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Until recently, the overdose crisis has been at the forefront of public health efforts in the United States (US). However, with the COVID-19 pandemic and rapid rise in cases across the country, attention has quickly shifted at the federal and state levels from overdose response to minimizing the spread of COVID-19. Rapid public health approaches have been implemented across jurisdictions, including widespread business closures, transitions to telemedicine, temporary closures of parks, and social distancing orders. While necessary to flatten the epidemiological curve of the pandemic, these public health approaches have largely failed to account for the unintended consequences such policies have on structurally vulnerable populations, including people who use drugs (PWUD).

Since 1999, there have been almost 450,000 overdose deaths in the US, with over 67,000 fatal overdoses in 2018 alone ([@bib0003]). Despite the ongoing severity of the overdose crisis, relatively little attention has been afforded to the impact of the now dual public health emergencies on PWUD as state governments focus on measures to address COVID-19. This oversight of co-occurring public health crises is concerning, given the ways in which social and structural factors, such as housing and work conditions, poverty, and criminalization are driving the impacts of both the overdose crisis and the COVID-19 pandemic for PWUD ([@bib0004]; [@bib0015]). Structurally vulnerable PWUD are more likely to be precariously housed, face barriers to accessing health care, and are more likely to be living with underlying chronic conditions that can exacerbate the severity of a COVID-19 infection, such as chronic obstructive pulmonary disease and HIV. It is therefore imperative that the COVID-19 response happens in tandem with the overdose response rather than in lieu of.

Overlapping public health crises {#sec0002}
================================

Since the onset of the COVID-19 pandemic in the US, there have been surges of fatal and nonfatal overdose events reported across the country ([@bib0001]). The precise causes of these spikes are unknown, but have been attributed to factors driven by the COVID-19 response, including physical distancing, stay-at-home orders, and difficulties accessing medications for opioid use disorder ([@bib0013]). Importantly, the increase in overdose events since COVID-19 underscores the need for bolstered state and local-level support for increased naloxone distribution efforts.

The distribution of take-home naloxone (THN) has been an instrumental, evidence-based response to minimizing fatal overdoses ([@bib0002]; [@bib0006]; [@bib0011]). Since first being rolled out in Europe and the US during the mid-1990s, THN programs have been rapidly expanded and have significantly reduced fatal overdoses ([@bib0007]; [@bib0014]; [@bib0018]). Despite its effectiveness, the COVID-19 pandemic has led to disruptions in naloxone distribution and access parts of the US as drop-in services reduce hours ([@bib0009]), challenging the ability for PWUD to have it readily available. Reduced harm reduction organization\'s hours and social distancing practices have meant that naloxone trainings have increasingly become digital, with naloxone kits mailed to participants afterwards. Street outreach teams have also faced difficulties reaching individuals as people have become more isolated since the pandemic. Further, harm reduction organizations have faced challenges in distribution efforts based on the closure of public areas (e.g. parks, buildings) where outreach is often conducted. These complications underscore the need for continued support in naloxone distribution across communities and amongst first responders, particularly as uptake of THN has been associated with having previously experienced an overdose, drug use injection, and being linked with harm reduction services ([@bib0008]; [@bib0010]; [@bib0016]).

Community-based responses {#sec0003}
=========================

Community-based harm reduction organizations have been leaders in rapidly and effectively responding to the overdose crisis and are now working to manage the compounding impacts of COVID-19 on their clients and staff. Through street outreach efforts, the widespread distribution of naloxone and fentanyl testing strips, and operating syringe service programs, harm reduction organizations have effectively reduced morbidity and mortality related to drug use and related outcomes. However, the impact of public health approaches to addressing COVID-19 have significant implications for the provision of needed health and ancillary services to PWUD and risk undermining tireless efforts of harm reduction organizations. Further, the prioritization of one public health emergency over another increases the public health gap that harm reduction organizations must fill while simultaneously applying for funding to stay afloat and seeking out innovative solutions to meet the needs of their client populations who have been overlooked in the COVID-19 public health response.

Across the country, harm reduction organizations have had to rapidly adapt their hours, outreach efforts, and programs and services so as to minimize COVID-19 exposure for both staff and clients as they manage with a dearth of personal protective equipment. A recent survey documented the impact of COVID-19 on over 150 syringe service programs across the US, with 43% reporting a reduction in services offered and 25% reporting site closures due to the pandemic ([@bib0009]). Such changes have meant that organizations have had to quickly find solutions to the now dual crises impacting their client populations, such as mail-based or delivery services of harm reduction supplies, including THN. While such innovative approaches are important for reaching particular populations who use drugs, they risk missing structurally vulnerable PWUD, including those who are unhoused or marginally housed or those who do not have access to internet technologies or cell phones. Some harm reduction organizations have therefore conducted home deliveries or increased street-based outreach efforts; while imperative, these efforts have been complicated by social distancing restrictions and the need to negotiate staff safety alongside that of their clients. As many harm reduction organizations are operated by people who have shared experiences with their clients, staff may be at higher risk of COVID-19 due to compromised immune systems from chronic conditions or other risk factors. This further challenges organizations' abilities to keep staff engaged in street outreach and home deliveries of needed supplies.

Expanding naloxone access and evidence-based harm reduction interventions {#sec0004}
=========================================================================

As overdose rates across the US have spiked during the COVID-19 pandemic, there is an urgent need to implement and scale up public health approaches aimed at minimizing fatal overdose risk. Such approaches should include removing regulatory barriers to expand naloxone access through community-based distribution ([@bib0005]). Doing so can further facilitate secondary naloxone distribution through networks of PWUD, expanding access to individuals who have limited access to harm reduction supplies. This is increasingly critically within the context of the COVID-19 pandemic as individuals are more isolated. Additionally, distributing THN in high-traffic areas, such as bus stations and transportation hubs, public washrooms, and shelters, may also reach a wider range of PWUD at risk of overdose.

Importantly, efforts to expand access to take-home naloxone must coincide with programs and policies that seek to comprehensively respond to the overdose crisis. This includes integrating low-barrier opioid agonist therapies (OAT) into existing harm reduction organizations and facilitating inductions onsite through telemedicine visits. While induction regulations in the US were expanded to include telemedicine visits within the context of COVID-19, the changes must be made permanent to make OAT more accessible to structurally vulnerable PWUD. Additionally, the provision of a safe supply of opioids (e.g. injectable hydromorphone, prescribed diacetylmorphine) should be implemented to minimize or eliminate exposure to illicitly manufactured fentanyl and related analogues. Such programs have been shown to be effective in other countries and should be expanded to the US ([@bib0012]; [@bib0017]).

Conclusions {#sec0005}
===========

As harm reduction organizations are critical to reducing health and drug-related harms for PWUD, the ripple effects of COVID-19 on these programs are likely to exacerbate the inequities faced by structurally vulnerable PWUD. Removing regulatory barriers that limit access to THN is an important step to addressing overdose risk amid this pandemic. Future research should examine how individuals who administer naloxone manage the unpredictability of overdose events in the context of a rapidly evolving drug supply, as well as the role of THN programs in rural and suburban communities, including how they might address drug-related discrimination and stigma.

As immediate concerns regarding surges in COVID-19 hospitalizations and deaths dissipate, governments must rapidly shift from a narrow view of the current crisis, to one that considers how social and structural inequities are exacerbating adverse health outcomes for particular populations. Doing so is critical to ethically addressing the ongoing public health emergencies and mitigating inequities for PWUD.
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